Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regenerative Medical Technology GroupRMTG -10.36% Net-Net Working Capital is $-3.00 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 818 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 122249.27% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
RMTG's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 5.3 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Regenerative Medical Technology Group (OTCPK:RMTG) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Regenerative Medical Technology Group Net-Net Working Capital Related Terms
Regenerative Medical Technology Group Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group Net-Net Working Capital Chart
RMTG vs ABPO, CLSDQ, SCNI: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Regenerative Medical Technology Group's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Regenerative Medical Technology Group's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $-3.00 mean?
Regenerative Medical Technology Group (RMTG) has a Net-Net Working Capital of $-3.00 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Regenerative Medical Technology Group According to the industry distribution chart, Regenerative Medical Technology Group ranks #999999 out of 818 companies in the Biotechnology industry.
Is Regenerative Medical Technology Group's Net-Net Working Capital too high?
Regenerative Medical Technology Group's current Net-Net Working Capital is $-3.00. Based on the distribution chart, Regenerative Medical Technology Group ranks #999999 out of 818 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regenerative Medical Technology Group's Net-Net Working Capital compare to ABPO and CLSDQ?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #999999 out of 818 companies for Net-Net Working Capital. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median Net-Net Working Capital is 5.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.30, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Regenerative Medical Technology Group For the Biotechnology industry, the median Net-Net Working Capital is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current Net-Net Working Capital is $-3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Fairly Valued. The stock's GF Value™ is $0.06, compared to a current price of $0.06 — trading 4.6% above its estimated fair value. The current Net-Net Working Capital is $-3.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Net-Net Working Capital is $-3.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 
